HealthyNCT05495373
Can Saliva be the New Bio-fluid to Monitor Children's Oral Health?
An observational study of Healthy, run by Hadassah Medical Organization at 1 site in Israel.
Trial summary
Background: Salivary diagnosis is an emerging field; the potentially valuable biofluid contains many molecules of the systemic circulation. Still, its profile in health has been scarcely investigated. Read more about this study
- Who is it for?
- Ages 4 to 12 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- How many people
- 100 participants
- Where
- 1 siteIsrael
- Study dates
- 1 Jan 2020to 1 Feb 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 to 12 years
- All sexes
- Healthy volunteers accepted
- Child
Study population: healthy children aged 4-12 visiting for routine dental treatment at hadassah medical center
Inclusion Criteria: healthy cases, no drug consumption or any chronic diseases. -
Exclusion Criteria: antibiotics in last 6 months, during any medical treatment other than dental care.
-
Trial locations and contacts
1 site in 1 country.
About this study
Background: Salivary diagnosis is an emerging field; the potentially valuable biofluid contains many molecules of the systemic circulation. Still, its profile in health has been scarcely investigated.
Aim: This study aimed to characterize the inflammatory profile of healthy children's saliva, and to associate the parameters with clinical diagnoses of caries and gingival inflammation.
Study design: Unstimulated saliva was collected from 100 children who underwent clinical dental examinations. The saliva samples were analysed for total protein, specific cytokines (IL-10, IL-8, IL-6 and TNF- α) and bacteria using Bradford assay, ELISA and quantitative real-time polymerase chain reaction, respectively. Salivary values were analysed according to age, plaque index (PI) and gingival index (GI).
Read the detailed description
Salivary diagnosis is an emerging field that has progressed through several important developments, including salivary proteome and the development of compact point-of-care devices for rapid analysis. Indeed, an increasing number of salivary markers have been identified; and some have been associated with cancer, cardiovascular diseases, autoimmune diseases, viral and bacterial diseases, and human immunodeficiency. Saliva is frequently studied due to the easy, non-invasive, and rapidly obtained collection, without the need for specialized equipment. Moreover, the prodigious fluid source of saliva provides many, if not most, of the molecules found in the systemic circulation, rendering it a potentially valuable bio-fluid for diagnoses.
Several types of inflammatory biomarkers associated with oral diseases, as well as systemic diseases, have been detected in saliva. Cytokines are among the most investigated biomarkers in this context. Due to their involvement in inflammatory, infectious and immunological diseases, cytokines may serve as markers of local oral pathologies such as periodontal disease and carries. Indeed, in adults, evidence shows that such disease can be detected through saliva biomarkers such as interleukins (IL)-1b, -6, -8 and -10), tumor necrosis factor- α (TNF- α) and matrix metalloproteinases (MMP)-8 and -9 in adults. Additionally, as some etiologies of oral pathology as gingivitis include bacterial infection such as Streptococcus, Fusobacterium, Actinomyces, Veillonella, Treponema, Capnocytophaga and Eikenella, saliva may also be used to measure bacterial load.
Dental caries is one of the most common childhood diseases worldwide, and is associated with polymicrobial colonization on tooth surfaces. Both acidogenic and aciduric bacteria, such as the Mutans group of Streptococci and Lactobacilli, are primary etiological agents of dental caries. Lactobacilli and S. Mutans are mostly found together in saliva . The diversity of microbes in saliva has been shown to increase in the caries active status. In children with cavitated carious lesions, altered concentrations of the cytokines IL-6 and IL-8 were reported.
The objective of this study was to characterize the inflammatory and microbiological profile of the saliva of healthy children, and to associate those levels with clinical diagnosis of caries and gingival disease.
Materials and methods Study population The study population comprised 100 participants, born during 2008-2016 (aged 4-12 years at the time of the study).
Clinical oral examination
Dental examinations were conducted by two dental students using a dental mirror, dental explorer and dental probe, and included the following parameters:
- Oral hygiene - measured by the plaque index (PI), as described previously,18 only on buccal surfaces.
- Periodontal status - measured by the gingival index (GI), as described previously
- Caries status measured by the DMFT/ dmft index (D=decay, M=missing, F=filling; T per tooth) in permanent/ primary dentition . All the values were collected and recorded in a data table.
Saliva collection Saliva was collected in a quiet room between 0800 and 1230 hr. The children were asked to collect saliva in their mouths and to spit it into a wide test tube for 3 min. The saliva was immediately stored at 4°C and further kept at -80°C until analysis. Data were collected onto paper charts, which were transferred to a computer program.
Bacteria testing Bacterial DNA was extracted from saliva using DNA extraction kit (Qiagen). The DNA was then tested using specific primers for total bacteria: Strep. Mutans, Lactobacillus and Fusobacterium nucleatum using quantitative real-time polymerase chain reaction.
Salivary cytokine quantification Salivary levels of human TNF- α, IL-10, IL-8, and IL-6 were measured using ELISA kits according to manufacturer instructions (R\&D systems, Minneapolis, MN, US). The saliva samples were transferred to the periodontal laboratory in Hadassah Ein Kerem Hospital for analysis. The ELISA method works by a cytokine carbonate-specific monoclonal antibody placed in a 96-well plate. After dilution of µL 83 saliva to 10 ml PBS of antibody capture, the active solution is placed with the antibody in the well, and covered overnight at room temperature. Subsequently, we wash with µL 400 (buffer wash) and repeat this step three times. We then block the wells by adding µL 300 diluent reagent for one hour at room temperature, and wash again as described above. We dilute at 100 µL, cover and incubate for 2 hours at room temp. We then rinse again, and add detection antibody at a concentration of 166 µL to 10 ml, cover and incubate for 2 hours. Next, we add biotin-related antibody, followed by HRP-streptavidin conjugate, and TMB as a substrate. The reaction is stopped by acid sulfuric and quantified using 650nm-OD490.
Statistical analysis All the experiments were performed in triplicate. The data were stratified according to age, DMF, PI and GI. Three age groups were set according to dental age: primary dentition - ages 0-6 years; mixed dentition - ages 6-11 years; and permanent dentition - above age 11 years. DMFT was stratified by ≤2 and >2. The PI was stratified by ≤1 and >1. GI was stratified by equal to zero versus above zero. The data were analysed using a statistical software package (SigmaStat, Jandel Scientific, San Rafael, CA, USA). One-way repeated measure analysis of variance (RM ANOVA) was applied to test the significance of the differences between the treated groups. When significant results were found, inter-group differences were tested for significance using the Student's t-test and the Bonferroni correction for multiple testing. Statistical significance was set at p<0.05.
- Conditions
- Healthy
- Keywords
- cytokines, saliva, gingivitis
- Medical subject headings
- Gingivitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| healthy cases | healthy children at ages between 4-12 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Oral hygiene
measured by the plaque index (PI)
Measured: at screening visit
Periodontal status
measured by the gingival index (GI)
Measured: at screening visit
Caries status
DMFT/ dmft index (D=decay, M=missing, F=filling; T per tooth) in permanent/ primary dentition
Measured: at screening visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2022
- Study start1 Jan 2020
- Primary completion1 Jan 2022
- Study completion1 Feb 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Hadassah Medical OrganizationThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hadassah Medical Organization
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Polak David, Hadassah Medical Organization
- Investigators
- david polak, Study chair, Hadassah Medical Organization
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05495373
- Sponsor's protocol ID
- HMO-067617
- Status last verified
- Aug 2022
- First submitted
- 18 Jul 2022
- Last updated
- 10 Aug 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Can Saliva be the New Bio-fluid to Monitor Children's Oral Health?
- ClinicalTrials.gov ID
- NCT05495373
- Acronym / sponsor ID
- HMO-067617
- Conditions
- Healthy
- Keywords
- cytokines, saliva, gingivitis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Hadassah Medical OrganizationUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 1 Jan 2022 (actual)
- Study completion
- 1 Feb 2022 (actual)
- First posted
- 10 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Salivary diagnosis is an emerging field; the potentially valuable biofluid contains many molecules of the systemic circulation. Still, its profile in health has been scarcely investigated.
Aim: This study aimed to characterize the inflammatory profile of healthy children's saliva, and to associate the parameters with clinical diagnoses of caries and gingival inflammation.
Study design: Unstimulated saliva was collected from 100 children who underwent clinical dental examinations. The saliva samples were analysed for total protein, specific cytokines (IL-10, IL-8, IL-6 and TNF- α) and bacteria using Bradford assay, ELISA and quantitative real-time polymerase chain reaction, respectively. Salivary values were analysed according to age, plaque index (PI) and gingival index (GI).
Detailed description
Salivary diagnosis is an emerging field that has progressed through several important developments, including salivary proteome and the development of compact point-of-care devices for rapid analysis. Indeed, an increasing number of salivary markers have been identified; and some have been associated with cancer, cardiovascular diseases, autoimmune diseases, viral and bacterial diseases, and human immunodeficiency. Saliva is frequently studied due to the easy, non-invasive, and rapidly obtained collection, without the need for specialized equipment. Moreover, the prodigious fluid source of saliva provides many, if not most, of the molecules found in the systemic circulation, rendering it a potentially valuable bio-fluid for diagnoses.
Several types of inflammatory biomarkers associated with oral diseases, as well as systemic diseases, have been detected in saliva. Cytokines are among the most investigated biomarkers in this context. Due to their involvement in inflammatory, infectious and immunological diseases, cytokines may serve as markers of local oral pathologies such as periodontal disease and carries. Indeed, in adults, evidence shows that such disease can be detected through saliva biomarkers such as interleukins (IL)-1b, -6, -8 and -10), tumor necrosis factor- α (TNF- α) and matrix metalloproteinases (MMP)-8 and -9 in adults. Additionally, as some etiologies of oral pathology as gingivitis include bacterial infection such as Streptococcus, Fusobacterium, Actinomyces, Veillonella, Treponema, Capnocytophaga and Eikenella, saliva may also be used to measure bacterial load.
Dental caries is one of the most common childhood diseases worldwide, and is associated with polymicrobial colonization on tooth surfaces. Both acidogenic and aciduric bacteria, such as the Mutans group of Streptococci and Lactobacilli, are primary etiological agents of dental caries. Lactobacilli and S. Mutans are mostly found together in saliva . The diversity of microbes in saliva has been shown to increase in the caries active status. In children with cavitated carious lesions, altered concentrations of the cytokines IL-6 and IL-8 were reported.
The objective of this study was to characterize the inflammatory and microbiological profile of the saliva of healthy children, and to associate those levels with clinical diagnosis of caries and gingival disease.
Materials and methods Study population The study population comprised 100 participants, born during 2008-2016 (aged 4-12 years at the time of the study).
Clinical oral examination
Dental examinations were conducted by two dental students using a dental mirror, dental explorer and dental probe, and included the following parameters:
- Oral hygiene - measured by the plaque index (PI), as described previously,18 only on buccal surfaces.
- Periodontal status - measured by the gingival index (GI), as described previously
- Caries status measured by the DMFT/ dmft index (D=decay, M=missing, F=filling; T per tooth) in permanent/ primary dentition . All the values were collected and recorded in a data table.
Saliva collection Saliva was collected in a quiet room between 0800 and 1230 hr. The children were asked to collect saliva in their mouths and to spit it into a wide test tube for 3 min. The saliva was immediately stored at 4°C and further kept at -80°C until analysis. Data were collected onto paper charts, which were transferred to a computer program.
Bacteria testing Bacterial DNA was extracted from saliva using DNA extraction kit (Qiagen). The DNA was then tested using specific primers for total bacteria: Strep. Mutans, Lactobacillus and Fusobacterium nucleatum using quantitative real-time polymerase chain reaction.
Salivary cytokine quantification Salivary levels of human TNF- α, IL-10, IL-8, and IL-6 were measured using ELISA kits according to manufacturer instructions (R\&D systems, Minneapolis, MN, US). The saliva samples were transferred to the periodontal laboratory in Hadassah Ein Kerem Hospital for analysis. The ELISA method works by a cytokine carbonate-specific monoclonal antibody placed in a 96-well plate. After dilution of µL 83 saliva to 10 ml PBS of antibody capture, the active solution is placed with the antibody in the well, and covered overnight at room temperature. Subsequently, we wash with µL 400 (buffer wash) and repeat this step three times. We then block the wells by adding µL 300 diluent reagent for one hour at room temperature, and wash again as described above. We dilute at 100 µL, cover and incubate for 2 hours at room temp. We then rinse again, and add detection antibody at a concentration of 166 µL to 10 ml, cover and incubate for 2 hours. Next, we add biotin-related antibody, followed by HRP-streptavidin conjugate, and TMB as a substrate. The reaction is stopped by acid sulfuric and quantified using 650nm-OD490.
Statistical analysis All the experiments were performed in triplicate. The data were stratified according to age, DMF, PI and GI. Three age groups were set according to dental age: primary dentition - ages 0-6 years; mixed dentition - ages 6-11 years; and permanent dentition - above age 11 years. DMFT was stratified by ≤2 and >2. The PI was stratified by ≤1 and >1. GI was stratified by equal to zero versus above zero. The data were analysed using a statistical software package (SigmaStat, Jandel Scientific, San Rafael, CA, USA). One-way repeated measure analysis of variance (RM ANOVA) was applied to test the significance of the differences between the treated groups. When significant results were found, inter-group differences were tested for significance using the Student's t-test and the Bonferroni correction for multiple testing. Statistical significance was set at p<0.05.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| healthy cases | – | –healthy children at ages between 4-12 |
Who may qualify
- Ages
- 4 to 12 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- healthy children aged 4-12 visiting for routine dental treatment at hadassah medical center
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Oral hygiene
Time frame: at screening visit
measured by the plaque index (PI)
Periodontal status
Time frame: at screening visit
measured by the gingival index (GI)
Caries status
Time frame: at screening visit
DMFT/ dmft index (D=decay, M=missing, F=filling; T per tooth) in permanent/ primary dentition
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2022.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
david polak study chair
Hadassah Medical Organization
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy, run by Hadassah Medical Organization at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Oral hygiene (time frame: at screening visit). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2022.